ReviewVirchows Archiv : an international journal of pathology2017
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.
Review in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reporting of somatic variants in clinical cancer care: recommendations of the Swiss Society of Molecular Pathology.Virchows Archiv : an international journal of pathology · 2024Guideline
- When genomics and histopathology diverge: insights from pathologic review of genomic-directed specimens.Virchows Archiv : an international journal of pathology · 2026Article
- Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?Journal of gastrointestinal cancer · 2026Review
- Inside the Matrix: Integrated Cytology and Molecular Testing of Thyroid FNAC Samples Using a Commercial Synthetic 3D Scaffold.International journal of molecular sciences · 2025Article
- Article
- Signalomics for molecular tumor boards and precision oncology of breast and gynecological cancers.Molecular systems biology · 2025Review
- Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.The oncologist · 2025Observational
- Internal Overview of Prostatic Cancer Cases and Quality ofDiagnostics (Basel, Switzerland) · 2024Article
- The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for DruggableInternational journal of molecular sciences · 2024Article
- Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer.British journal of cancer · 2024Review
- Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.The Lancet regional health. Europe · 2024Review
- Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.ESMO open · 2023Article
- Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.Journal of cancer research and clinical oncology · 2023Article
- Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management.Virchows Archiv : an international journal of pathology · 2022Review
- FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint.Journal of personalized medicine · 2022Review
- Molecular diagnosis in non-small-cell lung cancer: expert opinion onJournal of clinical pathology · 2022Review
- Utilisation of semiconductor sequencing for detection of actionable fusions in solid tumours.PloS one · 2022Article
- Road to FAIR genomes: a gap analysis of NGS data generation and sharing in the Netherlands.BMJ open science · 2022Article
- Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations.Oncotarget · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical demand for mutation detection within multiple genes from a single tumour sample requires molecular diagnostic laboratories to develop rapid, high-throughput, highly sensitive, accurate and parallel testing within tight budget constraints. To meet this demand, many laboratories employ next-generation sequencing (NGS) based on small amplicons. Building on existing publications and general guidance for the clinical use of NGS and learnings from germline testing, the following guidelines establish consensus standards for somatic diagnostic testing, specifically for identifying and reporting mutations in solid tumours. These guidelines cover the testing strategy, implementation of testing within clinical service, sample requirements, data analysis and reporting of results. In conjunction with appropriate staff training and international standards for laboratory testing, these consensus standards for the use of NGS in molecular pathology of solid tumours will assist laboratories in implementing NGS in clinical services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.